Table 4.
The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of Rheumatology) response criteria with combination adalimumab and methotrexate (ARMADA)15 and adalimumab monotherapy (van der Putte)16
|
ARMADA15 |
van der Putte et al16 |
|||
|---|---|---|---|---|
| MTX + placebo n = 67 | MTX + adalimumab 40 mg 2 weekly n = 62 | Placebo n = 113 | Adalimumab 40 mg 2 weekly n = 110 | |
| At 24–26 wks (%): | ||||
| ACR 20 | 15 | 67a | 19 | 46a |
| ACR 50 | 8 | 55a | 8 | 22 |
| ACR 70 | 5 | 27a | 2 | 12 |
Note:
a
P < 0.001 compared to placebo.
Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate.